ClinicalTrials.gg
RecruitingNCT06746714Updated Oct 14, 2026

Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients

An interventional study of Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia) and Usual care, after system-side dissemination of HOAP in Diabetes, sponsored by Kaiser Permanente. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jul 2023, registered Dec 2024).
  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Oct 14, 2026Now RecruitingSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Diabetes Mellitus by Kaiser Permanente — 2 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Kaiser Permanente.

Planned enrollment
11th of 23
250 · median 195
Started
2023
with 1 other
No phase
23 of 26
2 open now
Registered
24th of 26
by date

Among the 26 studies in Diabetes Mellitus by Kaiser Permanente, this one is the 11th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 23 with no phase, and was the 24th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 26 studies in Diabetes Mellitus by Kaiser Permanente are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Diabetes Mellitus by Kaiser Permanente, or all of them as a file.
02

Study summary

Severe low blood sugar (hypoglycemia) is a serious problem for people with diabetes. It can lead to dangerous falls, heart problems, memory issues, and even death. However, many healthcare providers don't recognize or manage this problem well. The investigators believe that creating a clear set of guidelines for preventing hypoglycemia, along with having a clinical pharmacist actively help high-risk patients, can make diabetes treatment safer.

In this study, the investigators developed a simple, evidence-based guide called "Hypoglycemia on a Page" (HOAP) to prevent low blood sugars. The investigators then tested it by comparing two groups of patients with type 2 diabetes who are at high risk for hypoglycemia. One group received active support from a clinical pharmacist using the HOAP guidelines, while the other group received standard care.

The main goal of this study is to see if the pharmacist's support leads to safer diabetes treatment. The investigators will also look at other factors, such as whether patients are prescribed glucagon (a medicine for severe low blood sugar), if they use continuous glucose monitoring, and whether they have worse blood sugar control or end up in the hospital for hypoglycemia. This trial aims to improve patient safety, health outcomes, and possibly lower healthcare costs.

Read the detailed description

The primary research question is whether using a "Hypoglycemia Champion" (HC) to target high risk patients with type 2 diabetes (T2D) is a feasible and effective model of care to reduce hypoglycemia risk in this population.

The goals of this study are to:

  1. Develop an evidence-based, expert consensus clinical guideline, "Hypoglycemia on a Page" (HOAP), for hypoglycemia prevention in patients with T2D at high risk of hypoglycemia. Guideline development will include stakeholders across multiple Kaiser Permanente regions.
  2. Develop a workflow for use by a "Hypoglycemia Champion" (HC), a clinical pharmacist who will apply the HOAP guideline in the proactive, protocol-driven management of Kaiser Permanente Northern California (KPNC) members identified as having high hypoglycemic risk;
  3. Conduct a pragmatic, randomized trial of the proactive HC intervention vs. usual care on diabetes regimen safety among KPNC members at high risk of hypoglycemia. The investigators hypothesize that at 6 months, high-risk members assigned to the HC intervention will be prescribed safer diabetes regimens (defined as discontinuation of sulfonylureas and/or rapid-/short-acting or mixed insulins) compared to usual care.

    The study design will include: 1) Engaging expert clinical stakeholders and experienced KP guideline developers to create an evidence-based hypoglycemia prevention algorithm (HOAP) analogous to KPNC's successful "PHASE on a Page" guideline for cardiovascular risk management; 2) Crafting a population-based workflow protocol for proactive outreach by the HC (specifically trained clinical pharmacist) to apply this new guideline to high-risk members; and 3) Performing a pragmatic randomized trial comparing proximal clinical outcomes (diabetes medication changes) available directly from the EHR between the intervention arm (pro-active outreach by the HC) vs. controls (usual care, including availability of the HOAP). The primary analysis will be intent-to-treat and will assess differences in the proportion of patients using safer diabetes regimens (relative to their baseline regimen) between study arms. The investigators will also examine heterogeneity of treatment effects by age, race/ethnicity, and prior severe hypoglycemia events. Deliverables include: 1) Inter-regional dissemination of the HOAP algorithm and the HC workflow protocol, 2) High quality, pragmatic RCT results to inform operational decision-making, and 3) Presentations and manuscripts to further disseminate findings. This study is highly relevant to TPMG and KP because: 1) Hypoglycemia is common, morbid, and costly, 2) Providers are challenged to address the competing demands of prescribing diabetes medications to meet glycemic targets while avoiding iatrogenic hypoglycemia, 3) No regional strategies currently exist to reduce hypoglycemia risk. This work has strategic implications for our organization because a new HEDIS measure proposed for measurement year 2023 will assess emergency department admissions for hypoglycemia in older adults with diabetes. The proposal will address this gap in organizational clinical care by developing and evaluating a practical, proactive, population management approach to hypoglycemia prevention for members with T2D at high risk of hypoglycemia.

  4. Conduct a prospective evaluation of whether proactive intervention by the Hypoglycemia Champion APM (i.e., assignment to augmented usual care group) is associated with reduced hypoglycemia among KPNC members with biochemical evidence of excess hypoglycemia, compared to usual care (control). The study will randomly assign eligible patients (patients who meet eligibility criteria and have "excess hypoglycemia" (>=4% time below range (TBR) on continuous glucose monitor (CGM) readouts)) to receive proactive intervention by the HC APM (augmented usual care group) for comparison to data-only patients receiving usual care. All eligible patients will be managed according to the regionally disseminated HOAP as the standard of care. All medical decisions for all patients (augmented usual care and usual care) are made by each member's medical care team responsible for his or her care (not by study personnel).
03

Conditions studied

  • Diabetes

Keywords

  • hypoglycemia
  • population management
  • clinical guideline
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Active KPNC members with valid MRNs at baseline (06/01/2023),
  2. age >=18 years,
  3. in the KPNC diabetes registry,
  4. likely type 2 diabetes (determined using a validated algorithm)
  5. high risk for hypoglycemia, determined using the hypoglycemia risk stratification tool developed by the investigator team

Exclusion criteria

Exclusion Criteria:

  1. Dementia or impaired cognition,
  2. psychosis or schizophrenia diagnosis,
  3. end-stage renal disease,
  4. "no contact" preferences on file,
  5. no primary care physician or home facility,
  6. receiving care at skill nursing facilities,
  7. deceased,
  8. enrolled in concurrent pharmacy deprescribing pilots
  9. Pregnant patients

Aim 4: In addition to criteria above, participants will only include patients with type 2 diabetes (T2D) who use a CGM device, have authorized sharing of their CGM data with their healthcare provider and have evidence of "excess hypoglycemia" (>=4% TBR on continuous glucose monitor readouts).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Intervention group, receiving protocol-driven outreach by a clinical pharmacist (the "hypoglycemia champion", or HC) to hypoglycemia-prone patients with T2D

    Behavioral: Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia)

  • Active comparator
    Usual care group

    Usual care, after system-wide dissemination of HOAP

    Behavioral: Usual care, after system-side dissemination of HOAP

Interventions

  • BehavioralProactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia)

    The Hypoglycemia Champion (HC) pharmacist reviewed patient charts before conducting proactive outreach. They did not contact subjects with active psychiatric issues or those admitted to a skilled nursing facility. The patient's care team (PCP and APM) were also contacted for peer consent. The outreach process involved an initial phone call with a secure electronic message or mailed letter (for those without secure KPNC patient portal access) if the initial call was unsuccessful. A second and third phone call attempt was made for non-responders.

  • BehavioralUsual care, after system-side dissemination of HOAP

    Patients had their diabetes treated as usual by their diabetes care provider or primary care physician, after system-wide dissemination of HOAP.

06

What researchers measure

Primary outcomes

  1. Number of patients with sulfonylureas, mealtime, or mixed insulin discontinued

    We will test for differences in the proportion of patients prescribed safer diabetes regimens (i.e., discontinuation of sulfonylureas, mealtime or mixed insulin)

    Time frame: 6 months

  2. Proportion of patient with "excess hypoglycemia"

    Proportion of patients with "excess hypoglycemia" (\>=4% TBR on continuous glucose monitor readouts) who achieve "acceptable levels of hypoglycemia" (\<4% TBR on continuous glucose monitor readouts), comparing study participants (augmented usual care) to data-only patients (usual care controls).

    Time frame: 6 months

Secondary outcomes

  1. Number of participants prescribed CGM

    The study will test for differences in the proportion of patients prescribed CGM

    Time frame: 6 months

  2. Number of participants prescribed glucagon

    The study will test for differences in the proportion of patients prescribed glucagon

    Time frame: 3, 6, 12 months

  3. Number of participants with A1c <8%

    The study will test for differences in the proportion of patients with good glycemic control (A1c \<8%)

    Time frame: 3, 6, 12 months

  4. Number of participants with ED visit or hospitalization for hypoglycemia

    The study will test for differences in the proportion of patients who had an ED visit or hospitalization for hypoglycemia

    Time frame: 6 months

  5. Percentage of patients who achieve "acceptable levels of hypoglycemia"

    Examine differences between study participants and data-only patients in the percentage of patients who achieve "acceptable levels of hypoglycemia"

    Time frame: 6 and 12 months

  6. Number of study PharmD visits

    The study will examine the differences between participant arms for the number of PharmD visits.

    Time frame: 3, 6, 12 months

  7. Diabetes Focused visits

    The study will examine the differences between participant arms for the number of diabetes focused visits.

    Time frame: 3, 6, 12 months

  8. Changes in insulin regimens

    The study will examine the differences between participant arms for the changes in insulin regimens.

    Time frame: 3, 6, 12 months

  9. Hypoglycemia on the problem list

    The study will examine the differences between participant arms for the presence of 'hypoglycemia' on the problem list.

    Time frame: 3, 6, 12 months

  10. ED visits/ hospitalizations (any cause)

    The study will examine the differences between participant arms for number of ED visits or hospitalizations, for any cause.

    Time frame: 3, 6, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Karter AJ, Warton EM, Lipska KJ, Ralston JD, Moffet HH, Jackson GG, Huang ES, Miller DR. Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. JAMA Intern Med. 2017 Oct 1;177(10):1461-1470. doi: 10.1001/jamainternmed.2017.3844. PubMed 28828479 ↗
  • Schroeder EB, Donahoo WT, Goodrich GK, Raebel MA. Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data. Pharmacoepidemiol Drug Saf. 2018 Oct;27(10):1053-1059. doi: 10.1002/pds.4377. Epub 2018 Jan 2. PubMed 29292555 ↗
  • Klompas M, Eggleston E, McVetta J, Lazarus R, Li L, Platt R. Automated detection and classification of type 1 versus type 2 diabetes using electronic health record data. Diabetes Care. 2013 Apr;36(4):914-21. doi: 10.2337/dc12-0964. Epub 2012 Nov 27. PubMed 23193215 ↗
  • Parker MM, Moffet HH, Adams A, Karter AJ. An algorithm to identify medication nonpersistence using electronic pharmacy databases. J Am Med Inform Assoc. 2015 Sep;22(5):957-61. doi: 10.1093/jamia/ocv054. Epub 2015 Jun 15. PubMed 26078413 ↗
  • Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009 Oct;44(5 Pt 1):1640-61. doi: 10.1111/j.1475-6773.2009.00989.x. Epub 2009 Jun 3. PubMed 19500161 ↗
  • Moffet HH, Adler N, Schillinger D, Ahmed AT, Laraia B, Selby JV, Neugebauer R, Liu JY, Parker MM, Warton M, Karter AJ. Cohort Profile: The Diabetes Study of Northern California (DISTANCE)--objectives and design of a survey follow-up study of social health disparities in a managed care population. Int J Epidemiol. 2009 Feb;38(1):38-47. doi: 10.1093/ije/dyn040. Epub 2008 Mar 7. No abstract available. PubMed 18326513 ↗
  • Hui RL, Chang CC, Niu F, Tang YK, Harano D, Deguzman L, Kao DJ, Awsare S, Draves M. Evaluation of a Pharmacist-Managed Antidiabetic Deprescribing Program in an Integrated Health Care System. J Manag Care Spec Pharm. 2019 Aug;25(8):927-934. doi: 10.18553/jmcp.2019.25.8.927. PubMed 31347983 ↗
  • Kaur U, Machado M, Mistry A. Hypoglycemia: A closer look at a community pharmacist's impact in optimizing diabetes care. J Am Pharm Assoc (2003). 2022 Sep-Oct;62(5):1686-1693.e6. doi: 10.1016/j.japh.2022.04.002. Epub 2022 Apr 12. PubMed 35550730 ↗
  • Whitfield N, Gregory P, Liu B, Spratt S, Smith BH. Impact of pharmacist outreach on glucagon prescribing. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1384-1388.e1. doi: 10.1016/j.japh.2022.01.017. Epub 2022 Jan 31. PubMed 35151583 ↗
  • Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005 Apr;11(4):253-60. PubMed 15839185 ↗
  • Lipska KJ, Warton EM, Huang ES, Moffet HH, Inzucchi SE, Krumholz HM, Karter AJ. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013 Nov;36(11):3535-42. doi: 10.2337/dc13-0610. Epub 2013 Jul 30. PubMed 23900589 ↗
  • Kunutsor SK, Balasubramanian VG, Zaccardi F, Gillies CL, Aroda VR, Seidu S, Khunti K. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes Obes Metab. 2024 Jun;26(6):2069-2081. doi: 10.1111/dom.15511. Epub 2024 Feb 26. PubMed 38409644 ↗
  • Vijayakumar P, Liu S, McCoy RG, Karter AJ, Lipska KJ. Changes in Management of Type 2 Diabetes Before and After Severe Hypoglycemia. Diabetes Care. 2020 Nov;43(11):e188-e189. doi: 10.2337/dc20-0458. Epub 2020 Sep 17. No abstract available. PubMed 32943439 ↗
  • Zhao Y, Shi Q, Wang Y, Fonseca V, Shi L. Economic burden of hypoglycemia: Utilization of emergency department and outpatient services in the United States (2005-2009). J Med Econ. 2016 Sep;19(9):852-7. doi: 10.1080/13696998.2016.1178126. Epub 2016 May 4. PubMed 27074526 ↗
  • Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ, Huang ES, Desai MM, Gill TM, Krumholz HM. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014 Jul;174(7):1116-24. doi: 10.1001/jamainternmed.2014.1824. PubMed 24838229 ↗
  • Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. JAMA. 2016 Nov 22;316(20):2115-2125. doi: 10.1001/jama.2016.16201. PubMed 27893129 ↗
  • Karter AJ, Moffet HH, Liu JY, Lipska KJ. Surveillance of Hypoglycemia-Limitations of Emergency Department and Hospital Utilization Data. JAMA Intern Med. 2018 Jul 1;178(7):987-988. doi: 10.1001/jamainternmed.2018.1014. PubMed 29710182 ↗
  • Gilliam LK, Parker MM, Chen MW, Karter AJ, Grant RW. Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk: A Randomized Clinical Trial. JAMA Netw Open. 2026 Feb 2;9(2):e2559946. doi: 10.1001/jamanetworkopen.2025.59946. PubMed 41706448 ↗

Individual participant data

Plan to share: No — The data generated and/or analyzed by the described study are not publicly available due to institutional policies but are available from the corresponding author on reasonable request and with the appropriate IRB approvals.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Mar 2027, 44 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 44 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jul 2024 → Mar 2027 and completion Dec 2024 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 24, 2024
StartActual
Jul 20, 2023
Primary completionEst.
Mar 31, 2027was Jul 2024
CompletionEst.
Dec 31, 2027was Dec 2024
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Oct 14, 2026
Sites
Kaiser Permanente Department of Research is now Recruiting
Oct 14, 2026
Primary completion
Jul 22, 2024→Mar 31, 2027
Oct 14, 2026
Study completion
Dec 20, 2024→Dec 31, 2027
Oct 14, 2026
Enrollment
200 (actual)→250 (estimated)
Oct 14, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria added
What changed in the criteria
Inclusion criteria
  • Editedlikely type 2 diabetes (determined using a validated algorithm)
Exclusion criteria
  • AddedPregnant patients
  • AddedAim 4: In addition to criteria above, participants will only include patients with type 2 diabetes (T2D) who use a CGM device, have authorized sharing of their CGM data with their healthcare provider and have evidence of "excess hypoglycemia" (>=4% TBR on continuous glucose monitor readouts).
Oct 14, 2026
Primary outcomes
1 added
What changed in the outcomes
  • AddedProportion of patient with "excess hypoglycemia"Time frame: 6 months
Oct 14, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41706448 ↗
Oct 14, 2026
Secondary outcomes
2 time frame changed, 6 added, 4 description edited
What changed in the outcomes
  • AddedPercentage of patients who achieve "acceptable levels of hypoglycemia"Time frame: 6 and 12 months
  • AddedNumber of study PharmD visitsTime frame: 3, 6, 12 months
  • AddedDiabetes Focused visitsTime frame: 3, 6, 12 months
  • AddedChanges in insulin regimensTime frame: 3, 6, 12 months
  • AddedHypoglycemia on the problem listTime frame: 3, 6, 12 months
  • AddedED visits/ hospitalizations (any cause)Time frame: 3, 6, 12 months
  • Time frameNumber of participants prescribed glucagon6 months → 3, 6, 12 months
  • Time frameNumber of participants with A1c <8%6 months → 3, 6, 12 months
  • DescriptionNumber of participants prescribed CGM: how it is measured was reworded
  • DescriptionNumber of participants prescribed glucagon: how it is measured was reworded
  • DescriptionNumber of participants with A1c <8%: how it is measured was reworded
  • DescriptionNumber of participants with ED visit or hospitalization for hypoglycemia: how it is measured was reworded
Oct 14, 2026
Contact
Study contact now listed: added l•••@kp.org · •••7584; added a•••@kp.org · •••5391. See the current contact
Oct 14, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Kaiser Permanente Department of Research · Pleasanton, United StatesContact added l•••@kp.org · •••7584Contact added a•••@kp.org · •••5391Contact added (no phone or email listed)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Completed→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41706448 ↗
    Kaiser Permanente Department of Research is now Recruiting
    Primary completion Jul 22, 2024→Mar 31, 2027
    Study completion Dec 20, 2024→Dec 31, 2027
    Enrollment 200 (actual)→250 (estimated)
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • Editedlikely type 2 diabetes (determined using a validated algorithm)
    Exclusion criteria
    • AddedPregnant patients
    • AddedAim 4: In addition to criteria above, participants will only include patients with type 2 diabetes (T2D) who use a CGM device, have authorized sharing of their CGM data with their healthcare provider and have evidence of "excess hypoglycemia" (>=4% TBR on continuous glucose monitor readouts).
    Primary outcomes 1 added
    What changed in the outcomes
    • AddedProportion of patient with "excess hypoglycemia"Time frame: 6 months
    Secondary outcomes 2 time frame changed, 6 added, 4 description edited
    What changed in the outcomes
    • AddedPercentage of patients who achieve "acceptable levels of hypoglycemia"Time frame: 6 and 12 months
    • AddedNumber of study PharmD visitsTime frame: 3, 6, 12 months
    • AddedDiabetes Focused visitsTime frame: 3, 6, 12 months
    • AddedChanges in insulin regimensTime frame: 3, 6, 12 months
    • AddedHypoglycemia on the problem listTime frame: 3, 6, 12 months
    • AddedED visits/ hospitalizations (any cause)Time frame: 3, 6, 12 months
    • Time frameNumber of participants prescribed glucagon6 months → 3, 6, 12 months
    • Time frameNumber of participants with A1c <8%6 months → 3, 6, 12 months
    • DescriptionNumber of participants prescribed CGM: how it is measured was reworded
    • DescriptionNumber of participants prescribed glucagon: how it is measured was reworded
    • DescriptionNumber of participants with A1c <8%: how it is measured was reworded
    • DescriptionNumber of participants with ED visit or hospitalization for hypoglycemia: how it is measured was reworded
    Contact Study contact now listed: added l•••@kp.org · •••7584; added a•••@kp.org · •••5391. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Kaiser Permanente Department of Research · Pleasanton, United StatesContact added l•••@kp.org · •••7584Contact added a•••@kp.org · •••5391Contact added (no phone or email listed)
    + 4 other changes: verification date, responsible party, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06746714
Lead sponsor
Kaiser Permanente
Responsible party
Lisa Gilliam (Chief of Endocrinology, South San Francisco Medical Center, Kaiser Permanente) — Principal investigator
First posted
Dec 24, 2024
Start date
Jul 20, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Lisa K Gilliam, MD, PhD
Contact
lisa.k.gilliam@kp.org
650-676-7584
Andrew J Karter, PhD
Contact
andy.j.karter@kp.org
206-817-5391
Lisa K Gilliam, MD, PhD
principal investigator · The Permanente Medical Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion